Pulmonx Reports Second Quarter 2024 Financial Results
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) reported strong financial results for Q2 2024. The company achieved record worldwide revenue of $20.8 million, a 21% increase year-over-year. U.S. revenue grew 26% to $13.9 million, while international revenue increased 12% to $6.9 million. Gross margin remained steady at 74%.
Key highlights include:
- Addition of 17 new Zephyr® Valve U.S. treatment centers
- First U.S. patients treated with AeriSeal® System in CONVERT II trial
- Net loss of $15.3 million, or $0.39 per share
- Adjusted EBITDA loss of $7.6 million
Pulmonx maintains its 2024 revenue guidance of $81-84 million and expects gross margin to be 74-75%.
Positive
- Record worldwide revenue of $20.8 million, up 21% year-over-year
- U.S. revenue growth of 26% to $13.9 million
- International revenue increase of 12% to $6.9 million
- Gross margin maintained at 74%
- Addition of 17 new Zephyr® Valve U.S. treatment centers
- First U.S. patients treated with AeriSeal® System in CONVERT II trial
Negative
- Net loss of $15.3 million in Q2 2024
- Adjusted EBITDA loss of $7.6 million
- Operating expenses increased by 6% to $30.9 million
- One-time, non-cash charge of $1.7 million for software impairment
News Market Reaction
On the day this news was published, LUNG declined 6.08%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024.
Recent Highlights
- Achieved record worldwide revenue of
$20.8 million in the second quarter of 2024, a21% increase over the same period last year and an increase of21% on a constant currency basis - Delivered
$13.9 million in U.S. revenue in the second quarter of 2024, representing26% year-over-year growth - Realized gross margin of
74% in the second quarter of 2024 - Added 17 new Zephyr® Valve U.S. treatment centers in the second quarter of 2024
- Treated first U.S. patients with the AeriSeal® System in CONVERT II pivotal clinical trial
- Eight scientific abstracts accepted for presentation at several upcoming key industry conferences
“Our record quarterly results reflect the continued traction of our commercial strategy, particularly in the United States where we continue to expand our presence by opening new accounts, preparing to launch new pilot programs to optimize patient workflows, and building local awareness of our Zephyr Valves,” said Steve Williamson, President, and Chief Executive Officer. “Our strategy is demonstrating positive momentum, giving us confidence in our ability to deliver our projected growth through the balance of the year and beyond.”
Second Quarter 2024 Financial Results
Total worldwide revenue in the second quarter of 2024 was
Gross profit in the second quarter of 2024 was
Operating expenses in the second quarter of 2024 were
Net loss in the second quarter of 2024 was
Adjusted EBITDA loss in the second quarter of 2024 was
Cash, cash equivalents, and marketable securities totaled
2024 Financial Outlook
Pulmonx continues to expect revenue for the full year 2024 to be in the range of
The Company continues to expect gross margin for the full year 2024 to fall within the range of
Pulmonx continues to expect total operating expenses for the full year 2024 to fall within the range of
Webcast and Conference Call Details
Pulmonx will host a conference call today, July 31, 2024, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.
Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.
The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations, such as impairment charges. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.
Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.
The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our commercial strategy to grow the adoption of our Zephyr Valve treatment and expand our global treatable market, our expectations regarding account activity and productivity, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, profitability, guidance for full year 2024, commercial momentum, physician engagement and awareness of the benefits of the Zephyr Valve, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on May 3, 2024, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Investor Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
| Pulmonx Corporation Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 20,783 | $ | 17,194 | $ | 39,637 | $ | 31,729 | ||||||||
| Cost of goods sold | 5,476 | 4,460 | 10,252 | 8,406 | ||||||||||||
| Gross profit | 15,307 | 12,734 | 29,385 | 23,323 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 5,615 | 5,710 | 9,825 | 9,963 | ||||||||||||
| Selling, general and administrative | 25,314 | 23,463 | 49,718 | 46,199 | ||||||||||||
| Total operating expenses | 30,929 | 29,173 | 59,543 | 56,162 | ||||||||||||
| Loss from operations | (15,622 | ) | (16,439 | ) | (30,158 | ) | (32,839 | ) | ||||||||
| Interest income | 1,306 | 1,410 | 2,747 | 2,537 | ||||||||||||
| Interest expense | (891 | ) | (864 | ) | (1,774 | ) | (1,435 | ) | ||||||||
| Other (loss) income, net | (35 | ) | (162 | ) | 380 | (54 | ) | |||||||||
| Net loss before tax | (15,242 | ) | (16,055 | ) | (28,805 | ) | (31,791 | ) | ||||||||
| Income tax expense | 84 | 140 | 270 | 264 | ||||||||||||
| Net loss | $ | (15,326 | ) | $ | (16,195 | ) | $ | (29,075 | ) | $ | (32,055 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.39 | ) | $ | (0.43 | ) | $ | (0.75 | ) | $ | (0.85 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 38,943,066 | 37,818,256 | 38,789,548 | 37,696,001 | ||||||||||||
| Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands) (Unaudited) | |||||||
| June 30, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 63,464 | $ | 83,547 | |||
| Restricted cash | 257 | 237 | |||||
| Short-term marketable securities | 51,081 | 33,555 | |||||
| Accounts receivable, net | 11,080 | 12,105 | |||||
| Inventory | 16,980 | 16,743 | |||||
| Prepaid expenses and other current assets | 3,297 | 4,235 | |||||
| Total current assets | 146,159 | 150,422 | |||||
| Long-term marketable securities | — | 14,390 | |||||
| Long-term inventory | 2,300 | 2,580 | |||||
| Property and equipment, net | 2,830 | 4,028 | |||||
| Goodwill | 2,333 | 2,333 | |||||
| Intangible assets, net | — | 31 | |||||
| Right of use assets | 18,490 | 3,406 | |||||
| Other long-term assets | 515 | 591 | |||||
| Total assets | $ | 172,627 | $ | 177,781 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 3,181 | $ | 1,497 | |||
| Accrued liabilities | 11,783 | 16,234 | |||||
| Income taxes payable | 66 | 93 | |||||
| Deferred revenue | 107 | 104 | |||||
| Short-term debt | 93 | 2,155 | |||||
| Current lease liabilities | 1,071 | 3,074 | |||||
| Total current liabilities | 16,301 | 23,157 | |||||
| Deferred tax liability | 118 | 114 | |||||
| Long-term lease liabilities | 17,914 | 1,106 | |||||
| Long-term debt | 37,110 | 35,089 | |||||
| Total liabilities | 71,443 | 59,466 | |||||
| Stockholders' equity | |||||||
| Common stock | 39 | 39 | |||||
| Additional paid-in capital | 539,408 | 526,797 | |||||
| Accumulated other comprehensive income | 1,973 | 2,640 | |||||
| Accumulated deficit | (440,236 | ) | (411,161 | ) | |||
| Total stockholders' equity | 101,184 | 118,315 | |||||
| Total liabilities and stockholders' equity | $ | 172,627 | $ | 177,781 | |||
| Pulmonx Corporation Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change (in thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | ||||||||||||||||
| 2024 | 2023 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| United States | $ | 13,881 | $ | 11,022 | 25.9 | % | — | % | 25.9 | % | ||||||
| International | 6,902 | 6,172 | 11.8 | % | (0.4 | )% | 12.2 | % | ||||||||
| Total | $ | 20,783 | $ | 17,194 | 20.9 | % | (0.1 | )% | 21.0 | % | ||||||
| Six Months Ended June 30, | ||||||||||||||||
| 2024 | 2023 | % Change | FX Impact % | Constant Currency % Change | ||||||||||||
| United States | $ | 26,750 | $ | 20,359 | 31.4 | % | — | % | 31.4 | % | ||||||
| International | 12,887 | 11,370 | 13.3 | % | 0.7 | % | 12.6 | % | ||||||||
| Total | $ | 39,637 | $ | 31,729 | 24.9 | % | 0.2 | % | 24.7 | % | ||||||
| Pulmonx Corporation Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA (in thousands) (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| GAAP Net loss | $ | (15,326 | ) | $ | (16,195 | ) | $ | (29,075 | ) | $ | (32,055 | ) | |||
| Depreciation and amortization | 400 | 409 | 823 | 846 | |||||||||||
| Stock-based compensation | 5,920 | 5,862 | 11,593 | 10,500 | |||||||||||
| Impairment of capitalized software development costs | 1,717 | — | 1,717 | — | |||||||||||
| Interest (income)/expense, net | (415 | ) | (546 | ) | (973 | ) | (1,102 | ) | |||||||
| Provision for income taxes | 84 | 140 | 270 | 264 | |||||||||||
| Adjusted EBITDA | $ | (7,620 | ) | $ | (10,330 | ) | $ | (15,645 | ) | $ | (21,547 | ) | |||
FAQ
What was Pulmonx's (LUNG) revenue for Q2 2024?
How much did Pulmonx's (LUNG) U.S. revenue grow in Q2 2024?
What was Pulmonx's (LUNG) gross margin in Q2 2024?
How many new Zephyr® Valve U.S. treatment centers did Pulmonx (LUNG) add in Q2 2024?
What is Pulmonx's (LUNG) revenue guidance for full-year 2024?
